DOSSIER · 13F-HR · Q1 2026

Vivo Capital, LLC

Vivo's hedge fund based in Chicago, IL $1.2B in tracked AUM across 46 positions as of Q1 2026.

V
Vivo·Chicago, IL·Hedge Fund
CIK 0001674712 · last filed Mar 31, 2026
Total AUM
$1.2B
1.3%
vs prior
Holdings
46
positions
Whale Score
67
67
tracked
Activity
no data
changes this Q
Top sector
Tech
7% weight
concentration
AI Analysis · Q1 2026 · Q1 2026
Portfolio Overview

Vivo Capital’s 13F as of 2025-09-30 shows a focused, concentrated long-equity portfolio of 37 reported U.S.-listed holdings with a market value of $677.73 million. The reported portfolio value declined 30.6% from $977.11 million on 2025-06-30. That decline is largely explained by large full exits reported this quarter (see Quarter Changes). Concentration is high: the top 10 holdings account for roughly 52% of the portfolio, while the top 5 represent about $203.4M or ~30.0% o...

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
ERAS
Erasca Inc
$197M12.2M16.3%
02
PRAX
Praxis Precision Medicines
$109M339K9.1%
03
TERN
Terns Pharmaceuticals Inc
$70M1.3M5.8%
04
TRVI
Trevi Therapeutics Inc
$61M5.1M5.1%
05
DBVT
DBV Technologies SA
$56M2.7M4.6%
06
CMPX
Compass Therapeutics Inc
$50M9.5M4.2%
07
TNGX
Tango Therapeutics Inc
$45M2.2M3.7%
08
SABS
SAB Biotherapeutics Inc
$44M11.4M3.6%
09
CRVS
Corvus Pharmaceuticals Holdings
$41M2.8M3.4%
10
DRUG
Bright Minds Biosciences Inc
$41M557K3.4%

Filing history

Filing history loading…